Financial Performance - The company reported net losses of $123.5 million and $106.5 million for the years ended December 31, 2023 and 2022, respectively, with an accumulated deficit of $416.3 million as of December 31, 2023[407]. - The company reported a net loss of $123.5 million for the year ended December 31, 2023, compared to a net loss of $106.5 million in 2022, indicating an increase in losses of approximately 15.5%[429][430]. - The net loss for 2023 was $123.5 million, compared to a net loss of $106.5 million in 2022, resulting in a net loss per share of $2.58[456]. - Total operating expenses for 2023 were $129.7 million, a 19.9% increase from $108.1 million in 2022, driven primarily by research and development expenses of $103.7 million[456]. - Total stockholders' equity decreased from $180.3 million in 2022 to $70.7 million in 2023, a decline of 60.8%[453]. Research and Development - Research and development expenses increased to $103.7 million in 2023 from $79.3 million in 2022, primarily driven by advancements in clinical-stage ADC programs and other pre-clinical programs[419]. - The increase in research and development expenses includes a $11.2 million rise for Phase 2 clinical-stage ADC programs and a $7.4 million increase for the CTLA4 immuno-oncology program[420]. - Research and development expenses accounted for approximately 80% of total operating expenses in 2023, underscoring the company's focus on product development[456]. - The company is advancing multiple clinical development programs, including mecbotamab vedotin, ozuriftamab vedotin, evalstotug, and BA3182, which will require substantial additional capital[407]. - The company anticipates that its expenses and capital requirements will increase substantially as it advances its clinical development efforts[407]. Cash and Liquidity - As of December 31, 2023, cash and cash equivalents totaled approximately $111.5 million, expected to fund operations for at least twelve months[410]. - Cash used in operating activities was $104.0 million in 2023, up from $90.4 million in 2022, reflecting a year-over-year increase of 15.8%[429][430]. - Cash and cash equivalents at the end of 2023 were $111.5 million, down from $215.5 million at the end of 2022, indicating a significant decrease in liquidity[461]. - The company plans to fund its ongoing losses through public or private equity or debt financings, with a potential gross sales proceeds of up to $100 million from an Open Market Sale Agreement[466]. - The company expects to face challenges in raising additional capital due to market volatility and other economic factors[428]. Collaborations and Revenue - The company has entered into collaborations and licensing agreements that may provide future milestone and royalty payments, but did not recognize any revenue from these agreements in 2023 or 2022[412]. - The company has not recognized any revenue from the BeiGene collaboration for the years ended December 31, 2023, and 2022[536]. - The collaboration agreement with Bristol-Myers Squibb did not impact the Company's financial results for the years ended December 31, 2023, or 2022[537]. Assets and Liabilities - As of December 31, 2023, the company reported total assets of $119.7 million, a decrease of 46.9% from $225.7 million in 2022[452]. - Total current assets decreased from $220.4 million in 2022 to $116.4 million in 2023, a decline of 47%[452]. - Total liabilities increased from $45.4 million in 2022 to $49.0 million in 2023, an increase of 5.8%[453]. - The company's accumulated deficit increased to $416.3 million in 2023, up from $292.8 million in 2022, reflecting ongoing operational losses[453]. Stock and Equity - The total number of common stock options outstanding increased from 2,736,918 in 2022 to 6,273,507 in 2023[495]. - The total number of restricted stock units increased from 510,039 in 2022 to 99,104 in 2023[495]. - The total number of common shares authorized for issuance under the 2020 Equity Incentive Plan increased to 9,196,970 in 2023 from 7,658,509 in 2022, an increase of 20.1%[520]. - The total unrecognized stock-based compensation cost for unvested common stock options was $15.6 million, expected to be recognized over approximately 2.8 years[527]. - The Company issued 165,550 shares under the Employee Stock Purchase Plan (ESPP) in 2023, compared to 147,564 shares in 2022[531]. Tax and Deferred Assets - The Company had federal net operating loss carryforwards of approximately $119.2 million, which can be carried forward indefinitely, subject to an 80% limitation against taxable income[554]. - The Company established a valuation allowance of approximately $85.6 million as of December 31, 2023, to offset deferred tax assets, which increased by approximately $28.9 million during 2023[553]. - The Company had gross unrecognized tax benefits of approximately $3.6 million as of December 31, 2023, none of which would affect the effective tax rate due to the valuation allowance[559]. Operational Insights - The impact of the COVID-19 pandemic on the company's operations remains uncertain and will depend on future developments[411]. - The Company views its operations as a single operating segment, streamlining performance assessment[470]. - The Company has not entered into any off-balance sheet arrangements as defined by SEC rules and regulations[440]. - The Company has not experienced any losses in its cash accounts and believes it is not exposed to significant credit risk[473].

BIOATLA REPORTS FOURTH QUARTER AND FULL YEAR 2023 FINANCIAL RESULTS AND HIGHLIGHTS RECENT PROGRESS – CAB-CTLA-4 (BA3071) Phase 1 study cleared dose-limiting toxicity (DLT) observation period with 700 mg (10 mg/kg); initial Phase 2 monotherapy data readout anticipated in 2Q 2024 and in combination with pembrolizumab in 2H 2024 – CAB-ROR2 (BA3021) Phase 2 melanoma and squamous cell carcinoma of the head and neck (SCCHN) clinical trials fully enrolled; on track for data readouts in 2Q 2024 – CAB-AXL (BA3011) P ...

Financial Data and Key Metrics Changes - Cash and cash equivalents as of September 30, 2023, were $141.3 million, down from $215.5 million as of December 31, 2022, with expectations to fund operations into the second half of 2025 [20] - Research and development expenses for Q3 2023 were $28.4 million, an increase from $19.8 million in Q3 2022, primarily due to clinical product development expenses [20] - General and administrative expenses were $6.6 million for Q3 2023, slightly up from $6.3 million in Q3 2022 [21] - Net loss for Q3 2023 was $33.3 million, compared to a net loss of $25.8 million in Q3 2022 [21] Business Line Data and Key Metrics Changes - BA3011 Phase II study in non-small cell lung cancer showed an objective response rate of 27.8% among patients previously treated with PD-1 therapy [7] - In patients with EGFR wild-type, non-squamous lung cancer, 33.3% had a partial response to BA3011 monotherapy [7] - BA3021, a CAB-ROR2-ADC, completed enrollment of approximately 20 patients in both lung cancer and melanoma studies, with early responses observed [11] Market Data and Key Metrics Changes - AXL expression in lung cancer is associated with poor prognosis, with patients in the study having a median of three prior lines of therapy [8] - The company is exploring the potential clinical benefits of BA3011 in AXL TmPS negative patients, which could broaden market opportunities [8] Company Strategy and Development Direction - The company aims to form strategic collaborations with major pharmaceutical partners to accelerate the development of selected assets [6] - Focus remains on delivering innovative therapies to cancer patients with significant unmet medical needs, particularly through the CAB platform [10] Management's Comments on Operating Environment and Future Outlook - Management received verbal FDA feedback supportive of a registrational path for BA3011 in lung cancer, with formal written feedback expected soon [26] - The company believes that the CAB platform demonstrates compelling clinical efficacy and safety across multiple therapeutic targets [23] Other Important Information - Dr. Bin Zhang joined as Senior Vice President, Head of Clinical Development and Operations, bringing over 20 years of experience in oncology drug development [18] - An abstract on BA3011 was accepted for presentation at the IASLC conference in December [19] Q&A Session Summary Question: Feedback on registrational path for BA3011 - Management received clear and actionable items from the FDA regarding the registrational path and expects to communicate more details in December [26] Question: Details on IASLC conference presentation - A standard poster presentation will include data sets, including spider plots and swimmers plots, with updates on combination therapy and more frequent dosing data [28][29] Question: Competition in non-small cell lung cancer - Management noted that responses at low AXL expression levels hint at broader market opportunities, with ongoing evaluations of AXL negative patients [33][35] Question: Data sharing for non-small cell lung cancer - Management confirmed that data on non-small cell lung cancer will be shared at an upcoming meeting, with a focus on prioritizing AXL lung for that indication [37] Question: Enrollment status for bispecific candidate BA3182 - Enrollment is progressing well, with the study actively dosing and showing positive early results [43]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, $0.0001 par value per share BCAB The Nasdaq Global Market FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to C ...

BioAtla, Inc. (NASDAQ:BCAB) Q2 2023 Earnings Conference Call August 1, 2023 4:30 PM ET Company Participants Bruce Mackle - IR, LifeSci Advisors, LLC Jay Short - Chairman & Chief Medical Officer Richard Waldron - Chief Financial Officer Eric Sievers - Chief Medical Officer Sheri Lydick - Chief Commercial Officer Conference Call Participants Brian Cheng - JPMorgan Kaveri Pohlman - BTIG Arthur He - H.C. Wainwright Tony Butler - E.F. Hutton Reni Benjamin - JMP Securities Operator Greetings, and welcome to the B ...

jay and car UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, $0.0001 par value per share BCAB The Nasdaq Global Market FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period fr ...

Conditionally Active Biologics: Transforming Cancer Therapy Corporate Presentation ...

BioAtla, Inc. (NASDAQ:BCAB) Q1 2023 Earnings Conference Call May 11, 2023 4:30 PM ET Company Participants Bruce Mackle - IR, LifeSci Advisors, LLC Jay Short - Chairman and CEO Richard Waldron - CFO Philippe Martin - Chief CDO Conference Call Participants Brian Cheng - JPMorgan Kaveri Pohlman - BTIG Reni Benjamin - JMP Securities Arthur He - H.C. Wainwright Operator Greetings. And welcome to the BioAtla First Quarter 2023 Earnings Conference Call. At this time, all participants are in a listen-only mode. A b ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, $0.0001 par value per share BCAB The Nasdaq Global Market FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commi ...

BioAtla, Inc. (NASDAQ:BCAB) Q4 2022 Earnings Call Transcript March 23, 2023 4:30 PM ET Company Participants Bruce Mackle - Investor Relations, LifeSci Advisors, LLC Jay Short - Chairman, Chief Executive Officer and Cofounder Richard Waldron - Chief Financial Officer Philippe Martin - Chief Clinical Development and Operations Conference Call Participants Brian Cheng - JPMorgan Kelly Shi - Jefferies Tony Buter - EF Hutton Arthur He - H.C. Wainwright Reni Benjamin - JMP Securities Operator Greetings. And welco ...